Mazvita Muchengeti

Mazvita Muchengeti

Auto-generated profile, based on publicly available information

Mazvita Muchengeti

National Cancer Registry, National Institute for Communicable Diseases, National Health Laboratory Services Johannesburg South Africa

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MSMazvita Sengayi‐Muchengeti
Mazvita Sengayi‐Muchengeti
WJWalburga Yvonne Joko‐Fru
Walburga Yvonne Joko‐Fru
AMAdalberto Miranda‐Filho
Adalberto Miranda‐Filho
MEMarcel Egue
Marcel Egue
MAMarie‐Therese Akele‐Akpo
Marie‐Therese Akele‐Akpo
DPDonald Maxwell Parkin
Donald Maxwell Parkin

9 October 2021 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
AKAhmadaye Ibrahim Khalil
Ahmadaye Ibrahim Khalil
TMTharcisse Mpunga
Tharcisse Mpunga
FWFeixue Wei
Feixue Wei
IBIacopo Baussano
Iacopo Baussano
CMCatherine de Martel
Catherine de Martel
GCGary M. Clifford
Gary M. Clifford
HIV substantially worsens human papillomavirus (HPV) carcinogenicity and contributes to an important population excess of cervical cancer, particularly in sub‐Saharan Africa (SSA). We estimated HIV‐ and age‐stratified cervical cancer burden at a country, regional and global level in 2020. Proportions of cervical cancer (a) diagnosed in women living with HIV (WLHIV), and (b) attributable to HIV, were calculated using age‐specific estimates of HIV prevalence (UNAIDS) and relative risk. These proportions were validated against empirical data and applied to age‐specific cervical cancer incidence (GLOBOCAN 2020). HIV was most important in SSA, where 24.9% of cervical cancers were diagnosed in WLHIV, and 20.4% were attributable to HIV (vs 1.3% and 1.1%, respectively, in the rest of the world). In all world regions, contribution of HIV to cervical cancer was far higher in younger women (as seen also in empirical series). For example, in Southern Africa, where more than half of cervical cancers were diagnosed in WLHIV, the HIV‐attributable fraction decreased from 86% in women ≤34 years to only 12% in women ≥55 years. The absolute burden of HIV‐attributable cervical cancer (approximately 28 000 cases globally) also shifted toward younger women: in Southern Africa, 63% of 5341 HIV‐attributable cervical cancer occurred in women <45 years old, compared to only 17% of 6901 non‐HIV‐attributable cervical cancer. Improved quantification of cervical cancer burden by age and HIV status can inform cervical cancer prevention efforts in SSA, including prediction of the impact of WLHIV‐targeted vs general population approaches to cervical screening, and impact of HIV prevention.

21 April 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MSMazvita Sengayi
Mazvita Sengayi
ASAdrian Spoerri
Adrian Spoerri
MEMatthias Egger
Matthias Egger
DKDanuta Kielkowski
Danuta Kielkowski
TCTamaryn Crankshaw
Tamaryn Crankshaw
JBJulia Bohlius
Julia Bohlius
The surveillance of HIV‐related cancers in South Africa is hampered by the lack of systematic collection of cancer diagnoses in HIV cohorts and the absence of HIV status in cancer registries. To improve cancer ascertainment and estimate cancer incidence, we linked records of adults (aged ≥ 16 years) on antiretroviral treatment (ART) enrolled at Sinikithemba HIV clinic, McCord Hospital in KwaZulu‐Natal (KZN) with the cancer records of public laboratories in KZN province using probabilistic record linkage (PRL) methods. We calculated incidence rates for all cancers, Kaposi sarcoma (KS), cervix, non‐Hodgkin's lymphoma and non‐AIDS defining cancers (NADCs) before and after inclusion of linkage‐identified cancers with 95% confidence intervals (CIs). A total of 8,721 records of HIV‐positive patients were linked with 35,536 cancer records. Between 2004 and 2010, we identified 448 cancers, 82% (n = 367) were recorded in the cancer registry only, 10% (n = 43) in the HIV cohort only and 8% (n = 38) both in the HIV cohort and the cancer registry. The overall cancer incidence rate in patients starting ART increased from 134 (95% CI 91–212) to 877 (95% CI 744–1,041) per 100,000 person‐years after inclusion of linkage‐identified cancers. Incidence rates were highest for KS (432, 95% CI 341–555), followed by cervix (259, 95% CI 179–390) and NADCs (294, 95% CI 223–395) per 100,000 person‐years. Ascertainment of cancer in HIV cohorts is incomplete, PRL is both feasible and essential for cancer ascertainment.

2 October 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RJRohini Janivara
Rohini Janivara
WCWenlong C. Chen
Wenlong C. Chen
UHUjani Hazra
Ujani Hazra
SBShakuntala Baichoo
Shakuntala Baichoo
IAIlir Agalliu
Ilir Agalliu
TRTimothy R. Rebbeck
Timothy R. Rebbeck

9 June 2022 in Journal of Medical Virology
Verified
Journal Article
Open access
MSMwiza Gideon Singini
Mwiza Gideon Singini
ESElvira Singh
Elvira Singh
DBDebbie Bradshaw
Debbie Bradshaw
TRThendo Ramaliba
Thendo Ramaliba
WCWenlong Chen
Wenlong Chen
FSFreddy Sitas
Freddy Sitas
We reviewed the literature on the importance of selected anti‐high‐risk human papillomavirus (HR‐HPV) antibodies (namely, 16/18 and early oncoproteins E6 and E7) as potential serological markers for early detection of individuals at high risk of cervical cancer. We searched for studies in PubMed and Embase databases published from 2010 to 2020 on antibodies against HR‐HPV E6 and E7 early proteins and cervical cancer. Pooled sensitivity and specificity for HPV16 and HPV18 antibodies were calculated using a bivariate hierarchical random‐effects model. A total of 69 articles were identified; we included three studies with 1550 participants. For the three HPV16/18 E6 and E7 antibody tests, enzyme‐linked immunosorbent assay‐based assays had a sensitivity of 18% for detecting CIN2+ (95% confidence interval [CI]: 15–21) and a specificity of 96% (95% CI: 92–98), for slot‐blot, sensitivity was 28.9% (95% CI: 23.3–35.1) and specificity was 72% (95% CI: 66.6–77.0) for detecting CIN2+, and for multiplex HPV serology assay based on a glutathione S ‐transferase, sensitivity was 16% (95% CI: 8.45–28.6) and specificity was 98% (95% CI: 97–99) for detecting invasive cervical cancer. HR‐HPV16/18 E6 and E7 serological markers showed high specificity, but sensitivity was suboptimal for the detection of cervical cancer in either population screening settings or as point‐of‐care screening tests.

15 September 2023 in International Journal of Cancer
Verified
Journal Article
Open access
EEEric A. Engels
Eric A. Engels
MSMeredith S. Shiels
Meredith S. Shiels
RBRuanne V. Barnabas
Ruanne V. Barnabas
JBJulia Bohlius
Julia Bohlius
PBPaul Brennan
Paul Brennan
GCGary M. Clifford
Gary M. Clifford
An estimated 38 million people live with human immunodeficiency virus (HIV) worldwide and are at excess risk for multiple cancer types. Elevated cancer risks in people living with HIV (PLWH) are driven primarily by increased exposure to carcinogens, most notably oncogenic viruses acquired through shared transmission routes, plus acceleration of viral carcinogenesis by HIV‐related immunosuppression. In the era of widespread antiretroviral therapy (ART), life expectancy of PLWH has increased, with cancer now a leading cause of co‐morbidity and death. Furthermore, the types of cancers occurring among PLWH are shifting over time and vary in their relative burden in different parts of the world. In this context, the International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) convened a meeting in September 2022 of multinational and multidisciplinary experts to focus on cancer in PLWH. This report summarizes the proceedings, including a review of the state of the science of cancer descriptive epidemiology, etiology, molecular tumor characterization, primary and secondary prevention, treatment disparities and survival in PLWH around the world. A consensus of key research priorities and recommendations in these domains is also presented.